Vaccine Contract Manufacturing Market by Vaccine Types (Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based), Workflows (Downstream [Packaging, Analytical & QC Studies, and Fill & Finish Operations], Upstream [Yeast Expression Systems, Bacterial Expression Systems, Mammalian Expression Systems, Baculovirus/Insect Expression Systems, and Others]), Applications (Human Use and Veterinary) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global vaccine contract manufacturing market size was valued at USD 2.65 billion and is expected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to owing to the rising demand for vaccines for the treatment and prevention from diseases.
Vaccines manufacturing is a process of developing and preparation of potential drugs for the treatment of diseases where expertise in the field is required. Apart from ensuring the safety and effectiveness of the treatment of disease, the vaccines produced are aimed at preventing or annihilation of diseases infection. The market is largely influenced by the rise of chronic illness and infectious diseases, which are varied from one country to other.
Massive expenditures in the installation and development of equipment, facilities, and hiring skilled labor that seeks to continue localize supply of essential materials and components for vaccines are some key factors expected to influence the acceptance of contract services. Moreover, certain countries need to update their equipment for manufacturing that requires them to indulge in partnerships with contract manufacturers to meet market demand. Increase in the number of product pipeline has fueled the demand for outsourcing services to decrease the timeline for their entry. Small scale and large scale firms are observed to be outsourcing to develop product pipeline at low cost.
Market Trends, Drivers, Restraints, and Opportunities
- Wide prevalence of infectious diseases and chronic illness along with the increasing number of the aging population globally is expected to boost the market.
- Increasing awareness about vaccination and its benefits to cure and prevent from disease among a large number of people in developing countries is further anticipated to spur the overall market expansion.
- Favorable government policies to expand regular immunization programs for children and infants presents a key driving factor of the market.
- Growing concerns for complications and financial requirement for vaccine production have pushed to focus on contract services for vaccine manufacturing. This is projected to propel the market expansion.
- Requirement of huge investments in equipment, facilities, and hiring skilled labor are some of the major restraining factors that can hamper the market growth.
Scope of the Report
The report on the global vaccine contract manufacturing market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Vaccine Contract Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Vaccine Types (Attenuated, Inactivated, Subunit-based, Toxoid-based, and DNA-based), Workflows (Downstream [Packaging, Analytical & QC Studies, And Fill & Finish Operations], Upstream [Yeast Expression Systems, Bacterial Expression Systems, Mammalian Expression Systems, Baculovirus/Insect Expression Systems, And Others]), and Applications (Human Use and Veterinary) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Lonza Group; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Ajinomoto Bio-Pharma Services, Inc.; Merck KGaA; Cytovance Biologics, Inc.; Catalent, Inc.; IDT Biologika GmbH; Albany Molecular Research, Inc.; PRA Health Sciences; ICON plc.; Pharmaceutical Product Development, LLC; Cobra Biologics; and Paragon Bioservices, Inc. |
Market Segment Insights
Attenuated segment is expected to grow at a rapid pace
Based on vaccine types, the global vaccine contract manufacturing market is divided into attenuated, inactivated, subunit-based, toxoid-based, and DNA-based. The attenuated segment is expected to grow at a rapid pace in the coming years owing to wide approval of large number of the vaccine types. However, the inactivated segment is anticipated to account for a key market share during the forecast period as they are safer and stable than other vaccine types.
Downstream segment is projected to expand at a considerable CAGR
On the basis of workflows, the market is bifurcated into downstream and upstream. The downstream segment is further divided into packaging, analytical & QC studies, and fill & finish operations. The upstream segment consists of yeast expression systems, bacterial expression systems, mammalian expression systems, baculovirus/insect expression systems, and others. The downstream segment is projected to expand at a considerable CAGR during the forecast period owing to a high requirement for biotechnological tools and skilled personnel. Meanwhile, the upstream segment is anticipated to constitute a considerable market share during the forecast period due to advancements in bioprocessing techniques.
Human use segment is expected to exhibit a robust growth rate
Based on applications, the global vaccine contract manufacturing market is bifurcated into human use and veterinary. The human use segment is expected to exhibit a robust growth rate during the targeted period owing to wide range of illness and disease infections in humans. On the other hand, the veterinary segment is anticipated to expand at a healthy CAGR during the forecast period due to increase in the demand for animal-based vaccines.
North America is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key share of the market in the coming years owing to widespread manufacturing of vaccines in the region. The market of Asia Pacific, however, is anticipated to grow significantly during the forecast period due to improving infrastructure and regulatory changes related to vaccine manufacturing and entering business contracts.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Vaccine Contract Manufacturing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Vaccine Contract Manufacturing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Vaccine Contract Manufacturing Market - Supply Chain
4.5. Global Vaccine Contract Manufacturing Market Forecast
4.5.1. Vaccine Contract Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Vaccine Contract Manufacturing Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Vaccine Contract Manufacturing Market Absolute $ Opportunity
5. Global Vaccine Contract Manufacturing Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
5.3.1. Attenuated
5.3.2. Inactivated
5.3.3. Subunit-based
5.3.4. Toxoid-based
5.3.5. DNA-based
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Vaccine Contract Manufacturing Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Vaccine Contract Manufacturing Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
7. North America Vaccine Contract Manufacturing Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
7.4.1. Attenuated
7.4.2. Inactivated
7.4.3. Subunit-based
7.4.4. Toxoid-based
7.4.5. DNA-based
7.5. Basis Point Share (BPS) Analysis by Types
7.6. Y-o-Y Growth Projections by Types
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
8. Latin America Vaccine Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
8.4.1. Attenuated
8.4.2. Inactivated
8.4.3. Subunit-based
8.4.4. Toxoid-based
8.4.5. DNA-based
8.5. Basis Point Share (BPS) Analysis by Types
8.6. Y-o-Y Growth Projections by Types
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
9. Europe Vaccine Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
9.4.1. Attenuated
9.4.2. Inactivated
9.4.3. Subunit-based
9.4.4. Toxoid-based
9.4.5. DNA-based
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
10. Asia Pacific Vaccine Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
10.4.1. Attenuated
10.4.2. Inactivated
10.4.3. Subunit-based
10.4.4. Toxoid-based
10.4.5. DNA-based
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
11. Middle East & Africa Vaccine Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Vaccine Contract Manufacturing Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Vaccine Contract Manufacturing Market Size and Volume Forecast by Types
11.4.1. Attenuated
11.4.2. Inactivated
11.4.3. Subunit-based
11.4.4. Toxoid-based
11.4.5. DNA-based
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Vaccine Contract Manufacturing Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Vaccine Contract Manufacturing Market: Market Share Analysis
12.2. Vaccine Contract Manufacturing Distributors and Customers
12.3. Vaccine Contract Manufacturing Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Lonza Group
12.4.2. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
12.4.3. Ajinomoto Bio-Pharma Services, Inc.
12.4.4. Merck KGaA
12.4.5. Cytovance Biologics, Inc.
12.4.6. Catalent, Inc.
12.4.7. IDT Biologika GmbH
Segments Covered in the Report
The global vaccine contract manufacturing market has been segmented on the basis of
Vaccine Types
- Attenuated
- Inactivated
- Subunit-based
- Toxoid-based
- DNA-based
Workflow
- Downstream
- Packaging
- Analytical & QC Studies
- Fill & Finish Operations
- Upstream
- Yeast Expression Systems
- Bacterial Expression Systems
- Mammalian Expression Systems
- Baculovirus/Insect Expression Systems
- Others
Applications
- Human Use
- Veterinary
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Lonza Group
- FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
- Ajinomoto Bio-Pharma Services, Inc.
- Merck KGaA
- Cytovance Biologics, Inc.
- Catalent, Inc.
- IDT Biologika GmbH
- Albany Molecular Research, Inc.
- PRA Health Sciences; ICON plc.
- Pharmaceutical Product Development, LLC
- Cobra Biologics
- Paragon Bioservices, Inc.
Key players competing in the vaccine contract manufacturing market are Lonza Group; FUJIFILM Diosynth Biotechnologies U.S.A., Inc.; Ajinomoto Bio-Pharma Services, Inc.; Merck KGaA; Cytovance Biologics, Inc.; Catalent, Inc.; IDT Biologika GmbH; Albany Molecular Research, Inc.; PRA Health Sciences; ICON plc.; Pharmaceutical Product Development, LLC; Cobra Biologics; and Paragon Bioservices, Inc. The main market players are continuously engaged in activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations.
Our Clients
Related Reports
Some other reports from this category!
